Glenmark Life Sciences IPO Details, Date, GMP, Review

Glenmark Life Sciences Limited is established in 2011 by Glenmark Pharmaceuticals Limited are the promoters of the company.

It is the world’s largest producer of Active Pharmaceutical Ingredients (APIs). The company creates, manufactures, and distributes high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, as well as gastrointestinal disorders, anti-infectives, and other therapeutic areas.

It also provides contract development and manufacturing operations (CDMO) to specialty pharmaceutical companies.

Updates :- Glenmark Life Sciences Limited IPO GMP / Grey market premium

Its products are sold in India as well as in other countries such as Europe, North America, Latin America, Japan, and so on. It currently operates four manufacturing facilities in Gujarat (Ankleshwar and Dahej) and Maharashtra (Mohol and Kurkumbh), with an annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive advantages

  • Leading producer of specialised APIs for chronic therapeutic areas such as CVS, CNS, diabetes, and pain management.
  • Products can be exported to Europe, Latin America, North America, Japan, and the rest of the world.
  • Strong relationships with the world’s leading generic companies.
  • Proven track record of financial success.
  • Manufacturing of high-quality products with R&D infrastructure.
  • Glenmark Life Sciences Limited IPO details
    Subscription Dates 27-29 July 2021
    Price Band 695-720 Rs Per Share
    Offer For Sale 453.60 crore
    Fress Issue size 1,060 crore
    Total IPO size 1,513.60 crore
    Minimum bid (lot size) 20 Rs Share
    Face Value 2 Rs share
    Retail Allocation 35%
    Listing On NSE, BSE
    Glenmark Life Sciences Market Lot
    Lot No of Shares Amount
    Minimum 1 20 Shares 14400 Rs
    Maximum 13 260 Shares 187,200 Rs

    Financial Record of the last year (In Million)

    Financial Period : 31-Mar-21
    Total Assets : 19,970.75
    Total Revenue : 18,859.76
    Profit After Tax : 3,515.81
    Earnings Per Share (EPS) FY2021 : 32.61 Rs

    Registrar of Glenmark Life Sciences IPO

    KFintech Private Limited
    KFintech, Tower-B, Plot No 31 & 32,
    Financial District, Nanakramguda, Gachibowli,
    Hyderabad, Telangana India – 500 032.
    Phone: 04067162222, 04079611000
    Email: [email protected]
    Website: https://karisma.kfintech.com/
    Website: http://www.linkintime.co.in

    Glenmark Life Sciences Contact Details

    Glenmark Life Sciences Limited
    Plot No. 170-172, Chandramouli Industrial Estate,
    Mohol Bazarpeth, Solapur 413 213,
    Phone: +91 2189 234456/ +91 2189
    Email: [email protected]
    Website: http://www.glenmarklifesciences.com/

    Leave a Reply

    Your email address will not be published. Required fields are marked *